Hormone Refractory Prostate Cancer

Oncology
9
Pipeline Programs
5
Companies
5
Clinical Trials
4
Approved Products

Pipeline by Development Stage

Preclinical
Phase 1
Phase 1/2
Phase 2
Phase 2/3
Phase 3
On Market
0
0
2
2
0
1
4
Early DiscoveryClinical DevelopmentMarket

Drug Modality Breakdown

Monoclonal Antibody
1100%
+ 4 programs with unclassified modality

On Market (4)

Approved therapies currently available

U
BILDYOSApproved
denosumab
Unknown Company
RANK Ligand Inhibitor [EPC]injection2025
U
BILPREVDAApproved
denosumab
Unknown Company
RANK Ligand Inhibitor [EPC]injection2025
Amgen
PROLIAApproved
denosumab
Amgen
RANK Ligand Inhibitor [EPC]subcutaneous2010
Amgen
XGEVAApproved
denosumab
Amgen
RANK Ligand Inhibitor [EPC]subcutaneous2010

Competitive Landscape

5 companies ranked by most advanced pipeline stage

Amgen
AmgenTHOUSAND OAKS, CA
1 program
1
1
DenosumabPhase 3Monoclonal Antibody1 trial
Active Trials
NCT00286091Completed1,435Est. Apr 2014
Oxford Biomedica
Oxford BiomedicaMA - Bedford
1 program
1
DocetaxelPhase 21 trial
Active Trials
NCT01194960Terminated25Est. Mar 2013
Bayer
BayerLEVERKUSEN, Germany
1 program
1
SargramostimPhase 21 trial
Active Trials
NCT00313482Terminated35Est. Aug 2008
C
CureVacGermany - Tübingen
1 program
1
CV9103Phase 1/21 trial
Active Trials
NCT00906243TerminatedEst. Dec 2010
M&
Merck & Co.RAHWAY, NJ
1 program
1
L-377202Phase 1/21 trial
Active Trials
NCT00987753Completed13Est. Nov 2001

Trial Timeline

Clinical trial activity over time

2021
2022
2023
2024
2025
2026
AmgenDenosumab
Oxford BiomedicaDocetaxel
BayerSargramostim
CureVacCV9103
Merck & Co.L-377202

Clinical Trials (5)

Total enrollment: 1,508 patients across 5 trials

NCT00286091AmgenDenosumab

Study on Prolonging Bone Metastasis-Free Survival in Men With Hormone Refractory Prostate Cancer

Start: Jan 2006Est. completion: Apr 20141,435 patients
Phase 3Completed
NCT01194960Oxford BiomedicaDocetaxel

TroVax® In Subjects With Hormone Refractory Prostate Cancer (HRPC)

Start: Aug 2010Est. completion: Mar 201325 patients
Phase 2Terminated
NCT00313482BayerSargramostim

PII Trial of Docetaxel/Prednisone w/Sargramostim for HRPC

Start: Apr 2006Est. completion: Aug 200835 patients
Phase 2Terminated
NCT00906243CureVacCV9103

RNActive®-Derived Therapeutic Vaccine

Start: May 2009Est. completion: Dec 2010
Phase 1/2Terminated
NCT00987753Merck & Co.L-377202

Study Evaluating the Safety and Tolerability of L-377202

Start: Mar 1999Est. completion: Nov 200113 patients
Phase 1/2Completed

Related Jobs in Oncology

Senior Research Associate, Immuno-Oncology

SystImmune
8m ago
$60K - $85K/yr

Research Associate I/II, Immuno-Oncology

SystImmune
8m ago

Office Administrator

SystImmune
8m ago
$60K - $80K/yr

Scientist/Sr Scientist

TwoStep Therapeutics
San Carlos
19m ago

Working Student Office Management Support (m/f/d)

Mindpeak
Hamburg
22m ago

Senior Medical Project Manager (m/f/d)

Mindpeak
Hamburg
22m ago

Phase Legend

Preclinical— Lab & animal studies
Phase 1— Safety & dosing
Phase 2— Efficacy testing
Phase 3— Large-scale trials
On Market— Approved & available

Key Insights

1 late-stage (Phase 3) programs — potential near-term approvals
5 companies competing in this space

Related Indications

Breast Cancer(530)Non-small Cell Lung Cancer(373)Prostate Cancer(371)Multiple Myeloma(244)Advanced Solid Tumors(221)Acute Myeloid Leukemia(204)Cancer(187)Neoplasms(173)Colorectal Cancer(166)Advanced Solid Tumor(165)